Clinical Trials Logo

Hypothermia, Induced clinical trials

View clinical trials related to Hypothermia, Induced.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05376267 Recruiting - Clinical trials for Hypoxia-Ischemia, Brain

Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)

Start date: August 5, 2022
Phase: N/A
Study type: Interventional

This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest. The study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome.

NCT ID: NCT04217551 Recruiting - Clinical trials for Hypoxia-Ischemia, Brain

Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients

ICECAP
Start date: May 18, 2020
Phase: N/A
Study type: Interventional

A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.

NCT ID: NCT03273075 Recruiting - Clinical trials for ACS - Acute Coronary Syndrome

Add-on Cangrelor in STEMI-triggered Cardiac Arrest

Start date: September 2017
Phase: Phase 4
Study type: Interventional

In patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary angioplasty (PCI) P2Y12 receptor (P2Y12r) inhibition should be achieved as soon as possible. Resuscitated STEMI-patients receiving targeted temperature management (TTM, therapeutic hypothermia) after cardiac arrest, however, show deteriorated and delayed early response to available oral P2Y12r inhibitors. Therapeutic hypothermia attenuates the drugs' effectiveness by reducing its gastrointestinal absorption and metabolic activation. Acute stent thrombosis is 5-fold increased after angioplasty following resuscitated cardiac arrest because of insufficient early platelet suppression. Thus, aggressive antiplatelet strategies are needed to achieve optimal platelet suppression during PCI in those patients. The first intravenous P2Y12r inhibitor, cangrelor, has recently received marketing authorization for the acute treatment of STEMI. We hypothesize that add-on antiplatelet therapy with intravenous Cangrelor on-top of standard dual anti platelet therapy (DAPT) with Prasugrel or Ticagrelor is superior to standard antiplatelet therapy alone in terms of suppressing ADP-dependent platelet activation in resuscitated STEMI-patients receiving TTM.

NCT ID: NCT02664194 Recruiting - Clinical trials for Myocardial Infarction

Hypothermia as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction

COOL-MI InCor
Start date: January 2016
Phase: N/A
Study type: Interventional

To evaluate and improve the safety and efficacy of hypothermia as an adjunctive therapy to percutaneous coronary intervention in patients with acute myocardial infarction.